Abstract B28: Development of next-generation breast cancer PDX models by applying intra mammary fat pad and intraductal tumor transfer

Abstract

Abstract Introduction: Worldwide, breast cancer is the second most common cancer after lung cancer and the leading cause of cancer death in women. These facts underline the urgent need for improved therapeutic options. However, with marked progress in the understanding of breast cancer biology, it has become obvious that breast cancer is not a single disease but a collection of very heterogeneous entities both between patients as well as within a tumor. This variability poses a major challenge for translational research and the development of new drugs. Most preclinical models fail to reproduce this inter- and intra-tumor heterogeneity which might at least partly contribute to the unacceptably high attrition rates in clinical testing. Although traditionally used in vivo models such as cell line xenografts have been of great value in the past, with the advent of personalized health care, improved models are required to properly reflect the complex physiology. Aim and experimental procedure: To this end, we aim at the development and evaluation of orthotopic patient-derived xenograft (PDX) models for breast cancer. Such PDX models have been shown repeatedly to preserve some tumor heterogeneity and a genetic profile similar to the original primary tumor. Specifically, two different approaches are tested to transfer primary tumor material to orthotopic locations in immunodeficient mice. On the one hand, small tumor fragments are transplanted into the mammary fat pad (i.mfp) and secondly, intraductal injection is applied for tumor cell transfer. We hypothesize that the intraductal implantation of primary tumor cells mimics breast carcinogenesis more closely than existing xenografts. Consequently, such a model would provide a unique system to study the whole spectrum of tumor progression to invasive and metastatic disease. Results: So far, five subcutaneously established PDX models, which were used for proof-of-concept studies, successfully engrafted using i.mfp transfer. As expected, histological analysis showed that tumor characteristics, such as expression of Her2, were faithfully retained in the grafted tumors. Intriguingly, two of the established PDX models tested were successfully injected intraductally and yielded invasive mammary carcinomas. These, to our knowledge, are the first breast cancer PDX models shown to grow invasively upon intraductal transfer. Furthermore, preliminary results showed an enhanced penetration of the tumor by lymphatic vessels after orthotopic transfer, especially after intraductal injection, compared to ectopic transplantation (subcutaneous), suggesting a more physiological growth and vessel supply. On top, we have observed tumor engraftment and invasive growth of seven primary samples (patient surgical specimen) upon i.mfp transfer, one of which also developed from intraductal injection, confirming that invasive tumors can form upon direct injection of patient material into milks ducts of mice. Conclusion and Outlook: Taken together, we want to create novel preclinical models for breast cancer which are able to provide a good phenocopy of several subtypes of human tumors and can consequently serve as models with improved predictivity. First results indicate that orthotopic transfer of breast PDX models displays a very physiological modeling of breast cancer and, importantly, that the most orthotopic placement of tumor cells (intra-ductal injection) allows invasive growth of breast tumor cells. In the future, we plan to include further models for intraductal injection to allow a thorough comparison between the two techniques and a reciprocal comparison to the original tumor. Additionally, application of the two implantation techniques in an immune-system humanized mouse background could provide very complex and physiological preclinical tools for cancer immunotherapeutic drug candidates. Citation Format: Lena Vockentanz, Adam Nopora. Development of next-generation breast cancer PDX models by applying intra mammary fat pad and intraductal tumor transfer. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr B28.